Dareen Siri
Expertise in
12
conditions

Dr. Dareen Siri

Allergy and Immunology
Ambulatory Medical Associates LLC
2010 Jacobssen Dr, 
Normal, IL 
Expertise in
12
conditions
Ambulatory Medical Associates LLC
2010 Jacobssen Dr, 
Normal, IL 

Overview

Dareen Siri is an Allergy and Immunologist in Normal, Illinois. Dr. Siri is highly rated in 12 conditions, according to our data. Her top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Sinusitis, and Allergic Rhinitis.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Allergy and Immunology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Ambulatory Medical Associates LLC
2010 Jacobssen Dr, Normal, IL 61761
Other Locations
Sneeze Wheeze & Itch Assoc L L C
2151 W White Oaks Dr, Springfield,, IL 62704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein
A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein
Enrollment Status: Completed
Publish Date: June 08, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

9 Total Publications

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Journal: Journal of the American Academy of Dermatology
Published: December 13, 2024
Similar Doctors
Expertise in
14
conditions
Dr. Julie Klemens
Allergy and Immunology
Expertise in
14
conditions
Dr. Julie Klemens
Allergy and Immunology

Facial Plastic & Laser Surgery

7301 N Knoxville Ave, 
Peoria, IL 
 (38.9 miles away)
309-589-5900
Languages Spoken:
English
See accepted insurances

Julie Klemens is an Allergy and Immunologist in Peoria, Illinois. Dr. Klemens is highly rated in 14 conditions, according to our data. Her top areas of expertise are Grass Allergy, Nonallergic Rhinopathy, Ozena, and Sinusitis.

Expertise in
7
conditions
Dr. Bethany Gibson
Allergy and Immunology
Expertise in
7
conditions
Dr. Bethany Gibson
Allergy and Immunology

Office

101 W McKinley Ave, 
Decatur, IL 
 (45.0 miles away)
217-876-3682
Languages Spoken:
English
See accepted insurances

Bethany Gibson is an Allergy and Immunologist in Decatur, Illinois. Dr. Gibson is highly rated in 7 conditions, according to our data. Her top areas of expertise are Sinusitis, Nonallergic Rhinopathy, Allergic Rhinitis, and Grass Allergy.

Expertise in
6
conditions
Dr. Stephen Smart
Allergy and Immunology
Expertise in
6
conditions
Dr. Stephen Smart
Allergy and Immunology

The Antioch Group Inc.

6615 N Big Hollow Rd, 
Peoria, IL 
 (41.2 miles away)
309-691-5200
Languages Spoken:
English
See accepted insurances

Stephen Smart is an Allergy and Immunologist in Peoria, Illinois. Dr. Smart is highly rated in 6 conditions, according to our data. His top areas of expertise are Chronic Spontaneous Urticaria (CSU), Vibratory Urticaria, Hives, and Allergic Rhinitis.

Frequently Asked Questions about Dr. Dareen Siri

How do I make an appointment with Dr. Dareen Siri?

You can book an appointment with Dr. Dareen Siri by calling their office at 309-452-0995. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dareen Siri a top-rated expert for Primary Immunodeficiency (PID)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dareen Siri is classified as an Distinguished expert for Primary Immunodeficiency (PID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dareen Siri specialize in?

While Dr. Dareen Siri is a Allergy and Immunology, they have specific expertise in Primary Immunodeficiency (PID), Common Variable Immune Deficiency, and Sinusitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Allergy and Immunology.

Does Dr. Dareen Siri participate in research or clinical trials?

Yes. Dr. Dareen Siri has published 9 articles and abstracts on conditions like Primary Immunodeficiency (PID). You can view a list of Dr. Dareen Siri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dareen Siri accept my insurance?

Dr. Dareen Siri accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 309-452-0995 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siri's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile